Cancer-Associated Fibroblasts Promote the Chemo-resistance in Gastric Cancer through Secreting IL-11 Targeting JAK/STAT3/Bcl2 Pathway

다국어 초록 (Multilingual Abstract)

Purpose Our aim was to detect the potential role of interleukin 11 (IL-11) in the development of chemo-resistance in gastric cancer and to reveal the mechanism involved in the process.
Materials and Methods Here, we used flow cytometry to examine the percentage of cancer-associated-fibroblasts in tumor samples from chemo-resistant and -sensitive gastric cancer patients. Using MTT assay, we detected the cell viability under different conditions. Using quantitative real-time polymerase chain reaction and Western blotting, we determined the target expressions in mRNA and protein levels. We also performed immunohistochemistry and immunofluorescence to detect the target proteins under different conditions. Animal models were constructed to verify the potential role of IL-11 in chemo-resistant develop in vivo.
Results Herein, we observed enriched cancer associated fibroblasts in drug resistant tumor tissues from gastric patients. Those fibroblasts facilitate the chemotherapeutic drugs resistance development through the secretion of IL-11, which activates the IL-11/IL-11R/gp130/ JAK/STAT3 anti-apoptosis signaling pathway in gastric cancer cells. We found that the combination of chemotherapeutic drugs and JAK inhibitor overcomes the resistance and increases the survival of mice with gastric cancer xenografts.
Conclusion Our results demonstrated that IL-11 contributed to the obtain of resistance to chemotherapy drugs through gp130/JAK/STAT3/Bcl2 pathway, and targeting the IL-11 signaling pathway induced by fibroblasts might be a promising strategy to overcome the multi-drugs resistant cancer in clinic.

참고문헌 (Reference)

1 Straussman R, "Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion" 487 : 500-504, 2012

2 Setrerrahmane S, "Tumor-related interleukins : old validated targets for new anti-cancer drug development" 16 : 153-, 2017

3 Sun Y, "Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B" 18 : 1359-1368, 2012

4 Danhier F, "To exploit the tumor microenvironment : passive and active tumor targeting of nanocarriers for anti-cancer drug delivery" 148 : 135-146, 2010

5 Varas-Godoy M, "The crosstalk between ovarian cancer stem cell niche and the tumor microenvironment" 2017 : 5263974-, 2017

6 Guerriero L, "The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells" 8 : 80393-80404, 2017

7 Sanchez-Lopez E, "Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling" 35 : 2634-2644, 2016

8 Baudino TA, "Targeted cancer therapy : the next generation of cancer treatment" 12 : 3-20, 2015

9 Zheng H, "TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling" 6 : 37070-, 2016

10 Zhu W, "Supramolecular hydrogels as a universal scaffold for stepwise delivering Dox and Dox/cisplatin loaded block copolymer micelles" 437 : 11-19, 2012

11 Ernst M, "STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice" 118 : 1727-1738, 2008

12 Ren C, "Plasma interleukin-11(IL-11)levels have diagnostic and prognostic roles in patients with pancreatic cancer" 35 : 11467-11472, 2014

13 Coley HM, "Overcoming multidrug resistance in cancer : clinical studies of p-glycoprotein inhibitors" 596 : 341-358, 2010

14 Quail DF, "Microenvironmental regulation of tumor progression and metastasis" 19 : 1423-1437, 2013

15 Johnson P, "Isolation of CD 90+ fibroblast/myofibroblasts from human frozen gastrointestinal specimens" e53691-, 2016

16 Johnston A, "IL-1F5, -F6, -F8, and-F9 : a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression" 186 : 2613-2622, 2011

17 Putoczki TL, "IL-11 signaling as a therapeutic target for cancer" 7 : 441-453, 2015

18 Gal P, "How signaling molecules regulate tumor microenvironment:parallels to wound repair" 22 : E1818-, 2017

19 Flach EH, "Fibroblasts contribute to melanoma tumor growth and drug resistance" 8 : 2039-2049, 2011

20 Paraiso KH, "Fibroblast-mediated drug resistance in cancer" 85 : 1033-1041, 2013

21 Turner N, "Fibroblast growth factor signalling : from development to cancer" 10 : 116-129, 2010

22 Nakayama T, "Expression of interleukin-11(IL-11)and IL-11 receptor alpha in human gastric carcinoma and IL-11upregulates the invasive activity of human gastric carcinoma cells" 30 : 825-833, 2007

23 Meads MB, "Environment-mediated drug resistance : a major contributor to minimal residual disease" 9 : 665-674, 2009

24 Johnstone CN, "Emerging roles for IL-11 signaling in cancer development and progression : focus on breast cancer" 26 : 489-498, 2015

25 Kikuchi K, "Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma" 166 : 709-723, 2017

26 Chua AC, "Dietary iron enhances colonic inflammation and IL-6/IL-11-Stat3 signaling promoting colonic tumor development in mice" 8 : e78850-, 2013

27 Cavaco A, "Collateral damage intended-cancer-associated fibroblasts and vasculature are potential targets in cancer therapy" 18 : E2355-, 2017

28 Tao L, "Cancerassociated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway" 6 : 38408-, 2016

29 Yu Y, "Cancerassociated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling" 110 : 724-732, 2014

30 Hwang RF, "Cancer-associated stromal fibroblasts promote pancreatic tumor progression" 68 : 918-926, 2008

31 Chen W, "Cancer statistics in China, 2015" 66 : 115-132, 2016

32 Holohan C, "Cancer drug resistance : an evolving paradigm" 13 : 714-726, 2013

33 De Araujo RF Jr, "Apoptosis in human liver carcinoma caused by gold nanoparticles in combination with carvedilol is mediated via modulation of MAPK/Akt/mTOR pathway and EGFR/FAAD proteins" 52 : 189-200, 2018

34 Juan TY, "Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity" 15 : 4600-4611, 2009